A British medical technology company has received a £2 million government-backed loan to accelerate an artificial intelligence platform designed to assist clinicians performing ear examinations outside of hospital settings. TympaHealth, which makes a combined ear and hearing health device for use in primary and community care, will use the Innovate UK funding to extend the clinical capabilities of its AI tool, Tympa Assist.

The investment reflects a growing effort within the health technology sector to push diagnostic-grade equipment further down the care pathway, reducing dependence on hospital appointments for conditions that do not require specialist intervention.

TympaHealth's platform combines high-definition digital otoscopy with AI-assisted image capture, wax assessment, hearing screening, microsuction and cloud-based referral management in a single system. It is designed for patients presenting with non-complex ear and hearing conditions in GP practices and community settings. The components are integrated, meaning a clinician does not need to switch between separate devices or systems during an assessment.

The Innovate UK loan will fund the development of new clinical diagnostic functions within Tympa Assist, the company's AI guidance layer. The tool assists practitioners with image quality, audiogram interpretation, wax assessment and referral decisions, though clinical judgement remains with the practitioner throughout.

Dr Krishan Ramdoo, an ENT surgeon and the company's founder, said the product is not designed to replace clinical reasoning. "AI is often associated with diagnosis, but that's not where the biggest challenge lies in everyday ear and hearing care," he said. "The real need at the frontline is consistency, confidence and knowing when to escalate." He described Tympa Assist as the first AI feature to run across the full ear and hearing health workflow, covering everything from image capture to the referral decision, while keeping the clinician in control.

The funding comes against a backdrop of significant strain on NHS ear, nose and throat and audiology services. ENT had the highest number of incomplete referral-to-treatment pathways for consultant-led elective care in England at 633,000, while audiology recorded the highest proportion of patients waiting six weeks or more out of all 15 tracked diagnostic tests, at 42.3% in November 2024, up five percentage points on the previous year. The government has acknowledged the scale of the problem. It stated that the community could provide around 30% of referrals currently made to ENT hospital departments. 

A report by the RNID published in March 2024 found that audiology services had reduced capacity in recent years owing to staff shortages and inadequate funding, pressures that were worsened by the pandemic. The charity recommended greater investment in technology-led innovation to trial new approaches to hearing care. The government's ten-year health plan for England, published in July 2025, said that people will in future be able to self-refer to clinical audiology where clinically appropriate, using the NHS App.

TympaHealth has not published a deployment timeline or indicated how many community settings it expects to reach with the upgraded platform. What the funding does signal is that government-backed innovation loans are increasingly being directed at companies attempting to redistribute clinical work rather than simply digitise what already exists in hospitals. For a medtech sector that has often struggled to demonstrate tangible impact on NHS waiting lists, a product positioned squarely at the referral decision rather than the diagnosis may prove to be a more tractable starting point.